Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Diphtheria toxin is a potent protein toxin produced by *Corynebacterium diphtheriae*. In the provided contexts, it is utilized as a research tool in genetically engineered mouse models that express the human diphtheria toxin receptor (hDTR). By binding to hDTR on specific cell types, the toxin is internalized, leading to the ADP-ribosylation of elongation factor 2 (eEF2) and subsequent inhibition of protein synthesis, ultimately causing cell death and depletion. This mechanism allows researchers to selectively ablate specific cell populations, such as urothelial cells or Foxp3+ regulatory T cells, to study their roles in various physiological and pathological processes like renal injury, autoimmune responses, cachexia, and anemia.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on diphtheria toxin.